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ABSTRACT  
Background: Sleep-disordered breathing (SDB) is under-diagnosed in chronic heart failure (CHF). 
Screening with simple monitors may increase detection of SDB in a cardiology setting. This study 
aimed to evaluate the accuracy of heart rate variability analysis and overnight pulse oximetry for 
diagnosis of SDB in CHF patients. 
Methods: 180 CHF patients underwent simultaneous polysomnography, ambulatory 
electrocardiography and wrist-worn overnight pulse oximetry. SDB was defined as an apnoea-
hypopnoea index >15/hour. To identify SDB from the screening tests, the percent very low frequency 
increment (%VLFI) component of heart rate variability was measured with a pre-specified cutoff 
>2.23%, and the 3% oxygen desaturation index was measured with a pre-specified cutoff >7.5 
desaturations/hour. 
Results: 173 CHF patients had adequate sleep study data; SDB occurred in 77(45%) patients. Heart 
rate variability was measurable in 78 (45%) patients with area under the %VLFI receiver operating 
characteristic curve of 0.50. At the >2.23% cutoff, %VLFI sensitivity was 58% and specificity 48%. The 
3% oxygen desaturation index was measurable in 171 (99%) patients with area under the curve of 
0.92. At the pre-specified cutoff of >7.5 desaturations/hour, the 3% oxygen desaturation index had 
sensitivity 97%, specificity 32%, negative likelihood ratio 0.08 and positive likelihood ratio 1.42. 
Diagnostic accuracy was increased using a cutoff of 12.5 desaturations/hour, with sensitivity 93% and 
specificity 73%. 
Conclusions: The high sensitivity and low negative likelihood ratio of the 3% oxygen desaturation 
index indicates that pulse oximetry would be of use as a simple screening test to rule out SDB in CHF 
patients in a cardiology setting. The %VLFI component of heart rate variability is not suitable for 
detection of SDB in CHF. 
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INTRODUCTION 
Sleep-disordered breathing (SDB) occurs in >50% chronic heart failure (CHF) patients [1 2] and despite 
an independent association with increased mortality [3 4], it is under-diagnosed [5]. Identification of 
CHF patients with SDB is complicated by the absence of classic symptoms such as excessive daytime 
sleepiness [6]. Additionally, polysomnography is recommended for the diagnosis of SDB in CHF [7] but 
these patients are often seen in cardiology clinics and access to this investigation may be limited. There 
is a need for simpler methods to enable the screening of CHF patients for SDB. 
Portable monitors such as overnight pulse oximetry have been used to diagnose obstructive sleep 
apnoea (OSA) in otherwise healthy adults but their utility in patients with comorbid medical conditions is 
unclear [8]. A recent international workshop report has highlighted the need for further research to 
evaluate the role of portable monitors in patients with SDB and CHF [9]. 
We have previously shown in a small study that analysis of heart rate variability (HRV) can be used to 
rule out SDB in patients with CHF [10]. HRV analysis can be performed during cardiological 
assessment and is potentially a convenient method to screen for SDB in CHF. The primary aim of this 
study was to prospectively evaluate the diagnostic performance of HRV analysis to detect SDB in a 
large number of CHF patients in a general cardiology setting. HRV analysis may not be possible in 
patients with cardiac arrhythmias or paced cardiac rhythm and our secondary aim was to evaluate 
pulse oximetry as a screening strategy for CHF patients unsuitable for HRV analysis. The following 
hypotheses were tested: 1) HRV analysis can be used to rule out SDB in patients with CHF; 2) 
Overnight pulse oximetry can be used to rule out SDB in CHF patients with atrial fibrillation, paced 
cardiac rhythm, frequent ectopic beats or artefact on ambulatory ECG monitoring; 3) HRV analysis has 
a higher accuracy than overnight pulse oximetry for the diagnosis of SDB in CHF.  
Some of the results of this study have previously been presented in abstract form [11 12]. 
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METHODS 
Patients with low or preserved ejection fraction heart failure were recruited from cardiology outpatient 
clinics. Inclusion criteria required a diagnosis of CHF in accordance with European guidelines [13], no 
hospitalisation or change in medication for >4 weeks, and age 18 – 90 years. Patients receiving 
treatment for SDB were excluded. Eligible patients were invited to participate irrespective of clinical 
suspicion of SDB. 
All patients underwent unattended polysomnography (SOMNOscreen, SOMNOmedics, Germany) with 
additional simultaneous recording with ambulatory electrocardiography (VistaPlus, Novacor, France) 
and wrist worn pulse oximetry (Pulsox 3i, Konica Minolta, Japan) on the same night. Patients were 
studied in their own home or in hospital according to their preference. Anthropometric measurements 
and clinical interview were completed before the sleep study with a behavioural maintenance of 
wakefulness test (OSLER) performed the next morning [14]. Full details of measurements are provided 
in the online supplement. 
Polysomnography studies were analysed by one person unaware of the clinical status of the patient, 
using standard scoring criteria [15]. Apnoea was scored when nasal airflow reduced to <10% of 
baseline for >10 seconds. Hypopnoea was scored when nasal airflow reduced by >50% of baseline 
with a >3% oxygen desaturation and/or electroencephalographic arousal (see also online supplement). 
SDB was defined as an apnoea-hypopnoea index (AHI) >15/hour and was categorised as central sleep 
apnoea (CSA) or OSA. 
The ambulatory electrocardiogram was recorded with a sampling frequency of 200Hz. HRV was 
analysed (Holtersoft, Novacor) during the period from midnight to 0600. Patients with paced cardiac 
rhythm, atrial fibrillation or >10% ectopic beats were excluded from HRV analysis. Manual editing was 
performed to ensure all QRS complexes were correctly identified. The spectral density of the heart rate 
increment was analysed for measurement of the percent very low frequency increment (%VLFI) [16]. 
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This component represents the very low frequency power (0.01 – 0.05Hz) of the heart rate increment 
power expressed as the percentage of total power (0.01 – 0.5Hz). An a priori %VLFI cutoff of >2.23% 
was used to diagnose SDB [10]. Recommended time domain and spectral components of HRV were 
also measured [17]. 
The wrist worn pulse oximeter recorded oxygen saturation with a sampling time of 5 seconds and data 
storage frequency of 0.2Hz. Overnight pulse oximetry was analysed (Download 2001, Stowood 
Scientific Instruments, U.K.) for >3% oxygen desaturations during the ‘time in bed’ period recorded by 
the patient. The 3% oxygen desaturation index (3% ODI) was calculated as the mean number of >3% 
oxygen desaturations per hour, using the ‘time in bed’ as denominator. A pre-specified 3% ODI cutoff of 
>7.5 desaturations/hour was used to diagnose SDB.  
Statistical Analyses 
An a priori sample size of 180 CHF patients was calculated to be adequately powered (1 - β = 80%) to 
detect a one sided difference of >10% between the sensitivity/specificity of HRV and polysomnography, 
at a significance level (α) of 0.05 (see online supplement). Results are presented as median and 
interquartile range (IQR). Continuous variables were compared with Mann-Whitney or Kruskal-Wallis 
tests. Categorical variables were compared using Fisher’s exact test or chi-square test. The diagnostic 
accuracy of the %VLFI and 3% ODI were compared by measurement of the area under the receiver-
operating characteristic (ROC) curve. Sensitivity, specificity, predictive values and likelihood ratios for 
the %VLFI and 3% ODI were determined at the a priori cutoffs. Statistical analyses were performed 
using SPSS V16.0 (IBM, Chicago, USA). 
 
RESULTS 
354 CHF patients were identified who fulfilled the recruitment criteria, 180 of whom consented to 
participate (Figure 1). 173 patients with adequate polysomnography data were included in the analysis, 
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with median age 69.8 (58.8 to 76.8) years, 86% male (Table 1). Most patients had mild to moderate 
symptomatic CHF with New York Heart Association class I or II symptoms in 77% and median left 
ventricle ejection fraction 40% (28 to 59%). 132 (73%) CHF patients had overnight monitoring 
performed in their home. 
Diagnosis of SDB from Polysomnography 
The median AHI was 13.5 (7.2 to 24.8) events/hour. SDB was diagnosed in 77 (45%) CHF patients with 
OSA in 53 (31%) patients and CSA in 24 (14%). As there was only a small number of CHF patients with 
CSA, all CHF patients with SDB were analysed as a single group. Body mass index, neck 
circumference and hip:waist ratio were significantly higher in CHF patients with SDB (Table 2). There 
were no significant differences in New York Heart Association class, brain natriuretic peptide (BNP) or 
left ventricle ejection fraction between CHF patients with and without SDB. Subjective and objective 
measures of sleepiness were similar irrespective of the presence or absence of SDB, but CHF patients 
with SDB had significantly more stage 1 sleep and higher arousal index (Table 3).  
Diagnostic Accuracy of HRV 
HRV was measurable in 78 (45%) CHF patients; the most common reasons for unsuitability for HRV 
measurement were paced cardiac rhythm or atrial fibrillation in 74 (43%) patients. Patients in whom 
HRV was measurable were significantly younger (p = 0.006) with a lower median BNP (p <0.001) and a 
trend to higher left ventricle ejection fraction (p = 0.08) compared to those in whom HRV could not be 
measured (Table E1 in online supplement). 
In the 78 (45%) CHF patients in whom HRV was measurable, SDB occurred in 36 (46%). The %VLFI 
component of HRV had a poor diagnostic accuracy for detection of SDB with an area under the %VLFI 
ROC curve of 0.50 (95% confidence interval 0.37 – 0.63, p = 0.99) (Figure 2). At the a priori cutoff of 
>2.23%, the %VLFI had sensitivity 58%, specificity 48%, positive likelihood ratio 1.11 and negative 
likelihood ratio 0.88 for diagnosis of SDB (Table E2). 
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The %VLFI was not correlated with the AHI (Spearman’s rho 0.005) and there was no significant 
difference in %VLFI according to the presence or absence of SDB (median %VLFI: CHF patients 
without SDB, 2.46% (1.45 to 4.41); CHF patients with SDB, 2.32% (1.19 to 5.08), p = 0.99). SDB was 
categorized as OSA in 31 (40%) patients with median %VLFI 2.35% (1.35 to 5.41); in 5 (6%) patients 
with CSA, median %VLFI was 0.78% (0.58 to 4.18). There was no significant difference between 
%VLFI in CHF patients with OSA, CSA or without SDB (p = 0.39). 
The diagnostic accuracy of %VLFI was assessed using alternative AHI thresholds of >5, >20 and >30 
events/hour for diagnosis of SDB. The area under the %VLFI ROC curve was similar at all AHI 
thresholds with no significant change in sensitivity or specificity (Table E2).  
Diagnostic Accuracy of Overnight Pulse Oximetry  
Overnight pulse oximetry could be analysed in 171 (99%) CHF patients in whom SDB was present in 
76 (44%). There was good agreement between 3% ODI and AHI (mean difference = -0.2 events/hour; 
Figure E1) with correlation coefficient (Spearman’s rho) of 0.84 (Figure E2). The 3% ODI had an area 
under the ROC curve of 0.92 (95% C.I. 0.88 - 0.96) for detection of SDB in CHF, indicating high 
diagnostic accuracy (Figure 3a). At the a priori cutoff of >7.5 desaturations/hour for diagnosis of SDB in 
CHF, two false negative results occurred with sensitivity 97% and negative likelihood ratio 0.08 (Table 
4). However, at this cutoff there were 65 false positive results with specificity 32% and positive 
likelihood ratio 1.42. In a post hoc analysis, a 3% ODI cutoff of >12.5 desaturations/hour reduced the 
number of false negative oximetry studies to 26, specificity increased to 73% (95% C.I. 64 – 81%), 
sensitivity 93% (95% C.I. 86 – 97%) and negative likelihood ratio 0.09 (95% C.I. 0.04 – 0.21). 
To investigate the utility of overnight pulse oximetry for diagnosis of SDB in CHF patients unsuitable for 
HRV analysis, the diagnostic accuracy of the 3% ODI was assessed in 94 patients in whom %VLFI was 
not measurable. In this subgroup, the 3% ODI had area under the ROC curve (AUC) of 0.92 (95% C.I. 
0.86 - 0.98; Figure 3b). At the cutoff of >7.5 desaturations/hour, the 3% ODI had sensitivity 98%, 
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specificity 24%, positive likelihood ratio 1.28 and negative likelihood ratio 0.10 for diagnosis of SDB in 
CHF patients unsuitable for HRV analysis (Table 4). 
Diagnostic Accuracy of HRV Analysis versus Overnight Pulse Oximetry 
To compare HRV analysis and overnight pulse oximetry for detection of SDB in CHF, the diagnostic 
accuracy of the 3% ODI was assessed in 77 patients in whom %VLFI was measurable (Table 4). In this 
subgroup, the 3% ODI had AUC of 0.91 (95% C.I. 0.85 - 0.98; Figure 3c) which was significantly 
greater than the AUC for the %VLFI (p <0.0001).  
 
DISCUSSION 
The main findings of this study were that the %VLFI component of HRV was unable to discriminate 
between the presence or absence of SDB in patients with CHF. Moreover, it could be measured in less 
than half of the CHF patients. In contrast, the 3% ODI was measurable in 99% of CHF patients, with an 
AUC of 0.92 indicating high accuracy for diagnosis of SDB. The 3% ODI had a superior diagnostic 
accuracy to the %VLFI for detection of SDB in CHF. 
Portable monitors provide a cost effective approach to improve access to OSA testing [18]. The 
simplest portable monitors record one or two physiological parameters with high accuracy for diagnosis 
of OSA in otherwise healthy adults [19 20]. The utility of these monitors to diagnose SDB in patients 
with comorbid cardiovascular disease has been identified as a research priority [9]. The findings of the 
present study help address this evidence gap. 
HRV analysis has been proposed as a simple screening test for detection of OSA [21 22]. The 
occurrence of SDB in CHF increases HRV [23], with increased very low frequency (<0.04Hz) 
oscillations in heart rate occurring during CSA [23 24] or OSA [23 25]. In individuals without CHF, the 
%VLFI has sensitivity 78 - 91% and specificity 34 - 70% for diagnosis of OSA [26 27]. In our previous 
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study of 33 CHF patients in whom HRV was measurable, the %VLFI had a sensitivity of 85% and 
specificity of 65% for diagnosis of SDB at an optimum cutoff of >2.23% [10]. The current study was 
designed to be adequately powered to prospectively evaluate this cutoff and has shown that the %VLFI 
can not be used to identify SDB in CHF. It is likely that the larger sample size and greater statistical 
power of the current study has provided a more accurate measure of the diagnostic utility of %VLFI in 
patients with CHF, highlighting the need for adequately powered trials in this area [9]. Moreover, our 
findings concur with those of Damy et al., who have also reported that %VLFI has a poor accuracy for 
SDB diagnosis in 54 CHF patients [28]. 
Potential reasons for the absence of a correlation between the %VLFI and AHI in patients with CHF 
include a reduction in HRV due to impaired autonomic cardiac reactivity [29]. Cardiac autonomic 
regulation and spectral components of HRV are significantly reduced by ageing [30] and the median 
age of patients in this study was higher than previous studies. Comorbidities such as diabetes, present 
in 26% of patients in this study, may have impaired autonomic function and reduced HRV. 
Cardiovascular medications are also likely to have influenced HRV in this study as beta blockers and 
ACE inhibitors can both increase the high frequency component of HRV through modulation of vagal 
cardiac input [31 32].  
Concomitant sleep disorders could potentially have influenced any relationship between the %VLFI and 
AHI. Periodic limb movements (PLM) occur frequently in CHF patients [1] and are associated with a 
significant increase in the %VLFI [26 33]. In the current study, a periodic limb movement index (PLMI) 
>5/hour was observed in 111 (64%) CHF patients. However there was no correlation between %VLFI 
and PLMI (Spearmans rho 0.01) and median %VLFI was not significantly different in patients with PLMI 
>5/hour compared to those with PLM <5/hour. Insomnia and sleep fragmentation unrelated to SDB are 
also prevalent in CHF and can increase the %VLFI [26]. In the current study, there was no correlation 
between the %VLFI and arousal index (Spearmans rho 0.034). Therefore, we do not think these factors 
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contributed to the present findings. 
Overnight pulse oximetry was simultaneously investigated as a simple screening test for the detection 
of SDB in CHF. Measurement of >2% or >4% oxygen desaturations has been reported to have high 
sensitivity to detect SDB in patients with low ejection fraction CHF [34 35]. In the current study, the 
AUC for the 3% ODI indicated a high diagnostic accuracy for detection of SDB in patients with low and 
preserved ejection fraction heart failure. At the a priori cutoff of >7.5 desaturations/hour, the 3% ODI 
had high sensitivity with a clinically useful negative likelihood ratio of 0.08, and would therefore be of 
greatest clinical use to rule out SDB in CHF. 
If overnight pulse oximetry was used as the initial investigation in a phased testing approach to detect 
SDB in CHF, further sleep studies would not have been required in 32 (33%) CHF patients without 
SDB. However, at the cutoff of >7.5 desaturations/hour, 3% ODI had poor specificity and low positive 
likelihood ratio. The diagnostic specificity of 3% ODI was increased at a cutoff of >12.5 
desaturations/hour without reduction in sensitivity. Using the 3% ODI cutoff of >12.5 desaturations/hour 
would have correctly identified and saved further sleep studies in 69 (73%) CHF patients without SDB. 
A limitation of the present study is that paced cardiac rhythm or atrial fibrillation prevented HRV 
analysis in 43% of CHF patients. Whilst HRV may still be measurable in patients with cardiac 
resynchronisation therapy (CRT) who are not atrial paced, and Cheyne-Stokes respiration can increase 
very low frequency HRV in patients with atrial fibrillation [36], the results of the current study suggest 
that this would be of no value to screen for SDB in CHF. A second consideration is that we did not meet 
our desired sample size as HRV could not be analysed in all 180 CHF patients recruited. However, 
further studies of the utility of %VLFI for diagnosis of SDB in CHF may not be an efficient use of 
resources; our results indicate a sample size of 780 CHF patients suitable for HRV analysis would be 
required to be adequately powered to exclude a >0.5% difference in %VLFI between CHF patients with 
and without SDB. A third consideration is that the small number of CHF patients with CSA precluded 
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comparison of the diagnostic accuracy of overnight pulse oximetry between patients with CSA and 
OSA. However, overnight oximetry has previously been reported to have 100% sensitivity for CSA in 
CHF [34] and in the current study, there were no false negative oximetry results in patients with CSA. 
A strength of this study is the recruitment of a heterogeneous population of CHF patients from 
cardiology clinics, 34% of whom had an ejection fraction >50%. Many previous studies have only 
enrolled patients with low ejection fraction heart failure but up to 50% of CHF patients have heart failure 
with preserved ejection fraction [37], and SDB may contribute to cardiac dysfunction in these patients 
[38]. In addition, despite inclusion of CHF patients with comorbidities including COPD and asthma 
which may influence overnight oxygen saturation, the diagnostic accuracy of the 3% ODI was high with 
AUC of 0.92. However, this may have contributed to the low specificity of pulse oximetry at the cutoff of 
>7.5 desaturations/hour. 
In summary, in CHF patients recruited from a cardiology setting, the 3% ODI cutoff of >7.5 
desaturations/hour had a high sensitivity of 97% and low negative likelihood ratio of 0.08 for diagnosis 
of SDB in CHF patients. Specificity of the 3% ODI was increased to 73% without reduction in sensitivity 
at an optimum 3% ODI cutoff of 12.5 desaturations/hour. In contrast, the %VLFI had a poor diagnostic 
accuracy and it can not be recommended to screen for SDB in patients with CHF. Overnight pulse 
oximetry would be of greatest clinical use to rule out SDB in patients with CHF, helping to reduce 
pressure on sleep laboratory facilities and prioritise those patients who may require more detailed sleep 
studies. 
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FIGURE LEGENDS 
 
Figure 1. Flow diagram to show recruitment of CHF patients and inclusion in heart rate variability 
analysis 
 
Figure 2. %VLFI ROC curve for diagnosis of SDB (AHI >15/hour) in patients with chronic heart failure. 
AUC = area under curve  
 
Figure 3. ROC curves showing diagnostic accuracy of 3% ODI for diagnosis of SDB in all CHF patients 
(n = 171; Figure 3a), in CHF patients in whom %VLFI could not be measured (n=94; Figure 3b) and 
CHF patients in whom %VLFI was measured (n=77; Figure 3c). AUC = area under curve. 
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TABLE 1. CLINICAL CHARACTERISTICS OF CHRONIC HEART FAILURE PATIENTS (n = 
173) 
Clinical Characteristic Value 
Age (years) 69.8 (58.8 – 76.8) 
Male (n,%) 148 (85.5) 
BMI (kg/m2) 29.1 (25.4 – 32.7) 
Neck size (cm) 40.0 (38.0 – 43.0) 
Waist/Hip ratio 1.02 (0.98 – 1.06) 
Diabetes (n,%) 44 (25) 
COPD/Asthma (n,%) 34 (20) 
Ischemic cardiomyopathy (n,%) 89 (51) 
Beta blocker therapy (n,%) 126 (73) 
ACEI/ARB therapy (n,%) 157 (91) 
Atrial fibrillation (n,%) 52 (30) 
Cardiac pacing (n,%) 50 (29) 
NYHA classification (I/II/III/IV) 24/110/37/2 
BNP (pg/ml) 118 (55 – 239) 
Left Ventricular ejection fraction (%) 40 (28 – 58) 
Definition of abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease; 
ACEI/ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker; NYHA = New 
York heart Association; BNP = B-type natriuretic peptide. 
Data are presented as median (interquartile range), or number (%) of patients.
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TABLE 2. COMPARISON OF CLINICAL CHARACTERISTICS IN CHRONIC HEART 
FAILURE PATIENTS WITH AND WITHOUT SLEEP-DISORDERED BREATHING 
 
No SDB (n = 96) SDB (n = 77) P Value 
Age (years) 71.9 (59.4 – 77.6) 66.7 (57.1 – 75.0) 0.08 
Male (n, %) 81 (84) 67 (87) 0.67 
BMI (kg/m2) 27.4 (24.8 – 31.6) 30.8 (27.8 – 35.4) <0.001 
Neck size (cm) 39.0 (37.0 – 41.0) 42.0 (39.5 – 43.0) <0.001 
Waist/Hip ratio 1.01(0.96 – 1.05) 1.03(0.99 – 1.07) 0.04 
Diabetes (n, %) 22 (23) 22 (29) 0.48 
COPD/Asthma (n, %) 27 (28) 7 (9) 0.002 
Ischemic cardiomyopathy (n, %) 54 (56) 35 (46) 0.17 
Beta blocker therapy (n, %) 62 (65) 64 (83) 0.009 
ACEI/ARB therapy (n, %) 87 (91) 70 (91) 1.0 
Atrial fibrillation (n, %) 26 (27) 26 (34) 0.41 
Cardiac pacing (n, %) 25 (26) 26 (34) 0.32 
NYHA classification (I/II/III/IV) 12/64/20/0 12/46/17/2 0.37 
BNP (pg/ml) 128 (69 – 201) 107 (42 – 322) 0.97 
Left Ventricle Ejection Fraction 
(%) 
40 (28 – 58) 43 (32 – 58) 0.76 
 
SDB = sleep-disordered breathing. See Table 1 for definition of additional abbreviations.  
Data are presented as median (interquartile range), or number (%) of patients
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TABLE 3. COMPARISON OF SLEEPINESS AND MEASUREMENTS OF SLEEP IN CHRONIC 
HEART FAILURE PATIENTS WITH AND WITHOUT SLEEP-DISORDERED BREATHING  
 
No SDB (n = 96) SDB (n = 77) P Value 
Epworth Score  7 (4 – 10) 7 (5 – 10) 0.45 
OSLER duration (minutes) 40 (39 – 40) 40 (27 – 40) 0.18 
HADS Score 12 (6 – 17) 11 (6 – 16) 0.78 
Total Sleep Time (minutes) 355 (285 – 401) 351 (295 – 408) 0.55 
Stage 1 sleep (% TST) 25 (14 – 42) 32 (21 - 48) 0.02 
Stage 2 sleep ( % TST) 39 (27 - 52) 38 (21 – 46) 0.15 
Deep sleep ( % TST) 11 (6 – 18) 10 (6 – 17) 0.73 
REM sleep ( % TST) 19 (15 – 25) 17 (13 – 24) 0.41 
Sleep efficiency (%) 69 (61 – 80) 74 (63 – 81) 0.26 
Arousal Index (events/hour) 16 (13 – 22) 24 (19 – 36) <0.001 
AHI (events/hour) 7.6 (4.1 – 11.0) 27.0 (19.2 – 40.6)  
Time SpO2 <90% (% TST) 1.1 (0.1 – 19.8) 8.3 (1.8 – 22.7) <0.001 
Baseline SpO2 (%) 93 (91 – 95) 94 (92 – 95) 0.62 
3% ODI*(events/hour) 9.1 (6.2 – 13.0) 24.4 (17.9 – 37.7) <0.001 
Periodic Limb Movement Index 
(events/hour) 
14 (2 – 33) 11 (3 – 42) 0.78 
Definition of abbreviations: OSLER = Oxford sleep resistance test; HADS = Hospital Anxiety and 
Depression score; TST = Total sleep time; REM = Rapid eye movement; AHI = Apnoea-
hypopnoea index; SpO2 = Oxygen saturation; ODI = Oxygen desaturation index 
Data are presented as median (interquartile range). 
*3% ODI measured from wrist worn pulse oximeter.
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TABLE 4. DIAGNOSTIC ACCURACY OF 3% OXYGEN DESATURATION INDEX FOR DETECTION OF SLEEP-DISORDERED 
BREATHING IN PATIENTS WITH CHRONIC HEART FAILURE 
 
 Sensitivity  Specificity  
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Positive 
Likelihood 
Ratio 
Negative 
Likelihood 
Ratio 
Area under 
ROC curve 
All CHF patients*  
(n = 171) 
97 
(91 – 100) 
32 
(22 – 41) 
53 
(45 – 62) 
94 
(79 – 99) 
1.42 
(1.24 – 1.64) 
0.08 
(0.02 – 0.34) 
0.92 
(0.88 – 0.96) 
CHF patients 
without %VLFI 
measurement*  
(n = 94) 
98 
(87 – 100) 
24 
(13 – 35) 
49 
(38 – 60) 
93 
(66 – 100) 
1.28 
(1.10 – 1.50) 
0.10 
(0.01 – 0.76) 
0.92 
(0.86 – 0.98) 
CHF patients with 
%VLFI 
measurement*  
(n = 77) 
97 
(85 – 100) 
41 
(26 – 57) 
59 
(47 – 72) 
94 
(73 – 100) 
1.66 
(1.28 – 2.16) 
0.07 
(0.01 – 0.48) 
0.91 
(0.85 – 0.98) 
Definition of abbreviations: ROC receiver operating characteristic; CHF chronic heart failure; %VLFI % very low frequency increment 
of heart rate variability 
*Diagnostic accuracy values were assessed using the a priori cutoff of >7.5 desaturations/hour for diagnosis of sleep-disordered 
breathing, and are presented with 95% confidence interval 
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FIGURE 1. 
 
 
354 CHF patients 
eligible for recruitment 
180 CHF patients 
enrolled and underwent 
overnight monitoring 
78 CHF patients 
suitable for heart rate 
variability analysis 
173 CHF patients 
included in final analysis 
Excluded: 
• - 43 could not be seen in clinic 
• - 95 declined to participate 
• - 23 could not be contacted after 
    receiving information sheet 
 - 13 worsening clinical status 
7 excluded due to insufficient sleep 
(<200 minutes total sleep time) 
95 CHF patients unsuitable for 
heart rate variability analysis 
- 45 Paced cardiac rhythm 
- 29 Atrial fibrillation 
- 13 Frequent ectopics 
-   5 No high frequency peak 
-   3 Technical failure 
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Figure a Figure b Figure c 
Diagnostic Accuracy of 3% ODI 
in CHF patients in whom %VLFI 
was not measurable (n=94) 
Diagnostic Accuracy of 3% ODI 
in CHF patients in whom %VLFI 
was measurable (n=77) 
Diagnostic Accuracy of 3% ODI 
in all CHF patients (n=171) 
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ONLINE DATA SUPPLEMENT 
 
Utility of Overnight Pulse Oximetry and Heart Rate Variability Analysis to Screen for 
Sleep-Disordered Breathing in Chronic Heart Failure 
 
Neil R. Ward, Martin R. Cowie, Stuart D. Rosen, Vitor Roldao, Manuel De Villa, Theresa A. 
McDonagh, Anita K. Simonds, Mary J. Morrell 
 
METHODS 
This study received ethical approval from the Brompton, Harefield and NHLI research ethics 
committee (COREC 07/Q0404/32) and participants gave informed consent before participation. 
Patients with low or preserved ejection fraction heart failure were recruited from cardiology 
outpatient clinics between November 2007 and May 2010 
Measurements 
Polysomnography (PSG) data was recorded with an ambulatory polysomnography system 
(SOMNOscreen, SOMNOmedics GmBH, Germany). Electroencephalogram (C3/A2; C4/A1), 
electroculogram and submental electromyogram (EMG) were recorded for analysis of sleep. 
Thoracoabdominal movements, nasal pressure and oxygen saturation were measured to assess 
respiration. The polysomnography oximeter updated oxygen saturation with each heart beat and 
used an averaging time of 4 heart beats; thus at a heart rate of 70 beats per minute, the 
oximeter averaging time would be 3.4 seconds which is similar to that recommended by the 
American Academy of Sleep Medicine [E1]. Snoring was detected with a tracheal microphone 
Page 24 of 35
http://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 2
and bilateral anterior tibialis EMG was monitored for identification of leg movements. Body 
position was monitored by an inbuilt sensor within the SOMNOscreen recording unit.   
Ambulatory electrocardiography was recorded synchronously using a commercial Holter monitor 
(VistaPlus, Novacor, Paris, France) to allow analysis of heart rate variability. Recording 
electodes were placed bilaterally below the sternoclavicular joints and over the 5th intercostal 
spaces in the anterior axillary line, with a fifth electrode located over the 4th intercostal space to 
the right of the sternal margin. A two channel ECG was recorded at a sampling rate of 200Hz. 
Data was recorded to a compact flash card which was downloaded and stored on a personal 
computer using proprietary software (Holtersoft, Novacor, France) the morning after each study. 
Overnight finger pulse oxygen saturation was also recorded with a separate wrist worn oximeter 
(Minolta Pulsox 3i, Konica Minolta, Osaka, Japan) used with a flexible finger probe (Konica 
Minolta Probe LM-5C) applied to a finger adjacent to the PSG oximeter. The recording 
characteristics of the Pulsox 3i include a sampling and averaging time of 5 seconds with a 
measurement value stored every 5 seconds. The oximeter was manually started by the 
researcher after attachment of all monitoring equipment. On the morning after the study, 
oximetry data was downloaded and stored on a personal computer using dedicated software 
(Download 2001, Stowood Scientific Instruments, Oxford, UK). 
All patients were asked to keep a diary to record the time that they turned out the light after 
going to bed and the time that they awoke the next morning. 
A structured clinical interview was conducted on the evening of the sleep study, to enquire about 
normal sleeping habits, snoring, sleep related symptoms, comorbid medical conditions and 
medication usage. Subjective daytime sleepiness was quantified with the Epworth sleepiness 
scale [E2] and the Hospital Anxiety and Depression score [E3] was used to screen for mood 
disorders. Anthropometric characteristics including height, weight, and circumference of neck, 
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waist and hip were measured. Spirometry was performed with the patient in a seated position, 
using a handheld spirometer (Vitalograph 2120, Maids Moreton, UK).  
Heart failure severity was assessed subjectively using the New York Heart Association 
classification [E4] and objectively by assay of B-type natriuretic peptide (BNP) and 
echocardiographic assessment of cardiac size and function. A blood sample for BNP assay 
(Triage BNP, Biosite Inc, California, USA) was collected from each participant on the morning 
after their sleep study. Echocardiography data was obtained by analysis of echocardiograms 
which had been performed as part of each patients routine clinical care. All echocardiograms 
were analysed by the same experienced echocardiographer who was unaware of the results of 
the other investigations.  
Data Analysis 
Polysomnography studies were scored by the same experienced polysomnographer who was 
unaware of the ambulatory ECG or pulse oximetry results. Sleep was scored according to 
standard criteria [E5]. Recommended definitions were used for analysis of respiratory events 
[E5]. Apnoea was scored when nasal airflow was reduced to <10% of baseline for > 10 seconds. 
Obstructive apnoeas were scored when the thoracoabdominal effort signals showed continuing 
respiratory excursions, whilst central apnoea was scored when respiratory efforts were absent. 
Hypopnoea was scored using the American Academy of Sleep Medicine ‘alternative’ rule, when 
nasal airflow reduced by > 50% of baseline with an associated oxygen desaturation of >3% 
and/or an EEG arousal from sleep [E5]. Obstructive hypopnoea was scored in the presence of 
snoring, flattening of the nasal pressure airflow signal or out of phase thorax and abdominal 
effort signals. Central hypopnoea was scored when all these features were absent. The mean 
number of apnoeas and hypopnoeas per hour of sleep was expressed as the apnoea-
hypopnoea index (AHI). SDB was defined as an AHI >15 events/hour and was further 
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categorised as obstructive or central sleep apnoea according to the predominant type of 
respiratory event. 
Anonymised ambulatory ECG recordings were analysed with a commercial software program 
(Holtersoft, Novacor, Rueil-Malmaison, France). CHF patients with paced cardiac rhythm for 
>10% of all QRS complexes, atrial fibrillation or >10% of ectopic beats were excluded from HRV 
analysis. Manual editing of the automated scoring was performed to ensure QRS complexes 
were correctly identified and to correct misidentified ectopic beats or artefact. Time spent on 
manual editing was limited to 20 minutes to ensure the technique was not too time consuming 
for use in the clinical setting. HRV was analysed during the period from midnight to 0600 [E6, 
E7]. In addition to measurement of recommended time domain and spectral components of HRV 
[E8], the spectral density of the heart rate increment (HRI) was also measured. Fourier transform 
was used to analyse the interbeat interval increment series through consecutive 16 min signal 
blocks to identify very low frequency oscillations in HRV. The %VLFI represents the percentage 
of the power in the very low frequency range (0.01 to 0.05 Hz) of the HRI power spectrum, 
expressed relative to the total spectral density power (0.01 – 0.5 Hz) [E9]. The diagnostic 
accuracy of %VLFI is increased when a simultaneous high frequency (HF) peak in the HRI 
power spectrum can be identified [E10]. Absence of the HF peak may occur in autonomic 
dysfunction, increasing the risk of a false negative result when %VLFI is used to screen for OSA 
[E10]. CHF patients without an identifiable HF peak were excluded from this analysis. 
Sample Size Calculation 
The required sample size was calculated to be adequately powered (1-β = 80%) to detect a one 
sided difference of >10% between the sensitivity/specificity of HRV and polysomnography at a 
significance level of 0.05. As there is no true gold standard for diagnosis of SDB, 
polysomnography was considered the reference standard and the method of Lui and 
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Cumberland was used to determine the number of patients required [E11]. The %VLFI 
component of HRV has previously been reported to have a sensitivity of 85% and specificity of 
65% to detect SDB in CHF [E6]. Using these values, it was calculated that 110 true positives 
were required to detect a >10% difference in sensitivity between polysomnography and %VLFI, 
whilst 180 true negatives were required to detect a >10% difference in specificity.  
 
RESULTS 
Characteristics of CHF patients in whom HRV was measurable are compared to patients 
unsuitable for HRV analysis in Table E1 
Use of different %VLFI cutoffs for SDB diagnosis  
A %VLFI cutoff of >2.4% has been reported to be the optimal cutoff value for detection of OSA in 
patients without CHF [E5]. In the current study, use of this threshold did not improve the 
diagnostic accuracy of %VLFI (Table E4). 
Diagnostic accuracy of the %VLFI was also calculated using the sleep diary times (%VLFIdiary). 
There was no significant improvement in sensitivity (56%), specificity (43%) or %VLFIdiary  AUC 
curve using this method (Table E4). 
Comparison of Alternative Measures of HRV in CHF patients with SDB 
Spectral and time domain components of HRV were also quantified in the 78 CHF patients in 
whom HRV was measurable (Table E5). There was a significant increase in absolute low 
frequency (LF) power in CHF patients with OSA compared to CHF patients without SDB or with 
CSA, although this difference was not seen when LF power was expressed in normalised units 
(nu). The percentage of adjacent NN intervals which differ by >50 milliseconds (pNN50) and the 
square root of the mean of the squares of differences between adjacent NN intervals (RMSSD) 
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time domain measurements (indicating rapid changes in heart rate through vagal modulation) 
also differed significantly between CHF patients without SDB and those with OSA and CSA. 
These HRV parameters showed improved diagnostic accuracy compared to %VLFI with AUC of 
0.69 (95% confidence interval 0.57 - 0.80) for absolute LF power, 0.71 (95% C.I. 0.60 - 0.83) for 
pNN50, and 0.70 (95% C.I. 0.58 - 0.81) for RMSSD (ROC curves not shown). 
Comparison of Accuracy of %VLFI and 3% ODI for SDB diagnosis in CHF 
%VLFI was measurable in 78 CHF patients, with AUC of 0.50 (standard error 0.067) for 
diagnosis of CHF. 3% ODI was measured in 77 of these 78 CHF patients (one overnight pulse 
oximetry technical failure) with AUC of 0.91 (standard error 0.033). There was a significant 
difference in area beneath the %VLFI and 3% ODI ROC curves of 0.41 (standard error 0.074; p 
<0.0001). 
 
 
ONLINE SUPPLEMENT REFERENCES 
E1.  Redline S, Budhiraja R, Kapur V, et al. The scoring of respiratory events in sleep: 
reliability and validity. J Clin Sleep Med 2007;3(2):169-200. 
E2. Johns, M.W., A new method for measuring daytime sleepiness: the Epworth sleepiness 
scale. Sleep, 1991;14(6):540-5. 
E3. Zigmond, A. and R. Snaith, The hospital anxiety and depression scale. Acta Psychiatr 
Scand, 1983;67(6):361-70. 
E4. The Criteria Committee of the New York Heart Association.  Nomenclature and Criteria 
for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed ed. Boston, Mass: Little, Brown 
& Co. 1994:253-6 
Page 29 of 35
http://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 7
E5 Iber C, Ancoli-Israel S, Chesson A, et al. The AASM Manual for the Scoring of Sleep and 
Associated Events: Rules, Terminology and Technical Specifications. 1st ed. 2007: 
Westchester, Illinois: American Academy of Sleep Medicine. 
E6 Roche F, Celle S, Pichot V, et al. Analysis of the interbeat interval increment to detect 
obstructive sleep apnoea/hypopnoea. Eur Respir J. 2007;29:1206-11. 
E7 Vazir A, Dayer M, Hastings PC, et al. Can heart rate variation rule out sleep-disordered 
breathing in heart failure? Eur Resp J, 2006. 27(3):571-577. 
E8. Task Force of the European Society of Cardiology, Heart rate variability. Standards of 
measurement, physiological interpretation, and clinical use. Task Force of the European Society 
of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J, 
1996. 17(3):354-81. 
E9 Roche F, Duverney D, Court-Fortune I, et al. Cardiac interbeat interval increment for the 
identification of obstructive sleep apnea. Pacing Clin Electrophysiol, 2002. 25(8):1192-1199. 
E10. Poupard L, Court-Fortune I, Pichot V, et al. Use of high-frequency peak in spectral 
analysis of heart rate increment to improve screening of obstructive sleep apnoea. Sleep Breath. 
2011 Dec;15(4):837-43  
E11. Lui, K.J. and W.G. Cumberland, Sample size determination for equivalence test using 
rate ratio of sensitivity and specificity in paired sample data. Control Clin Trials, 2001. 22(4):373-
89 
Page 30 of 35
http://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 8
 
TABLE E1. COMPARISON OF CHRONIC HEART FAILURE PATIENTS SUITABLE AND 
UNSUITABLE FOR HEART RATE VARIABILITY ANALYSIS 
 Patients suitable for 
HRV analysis 
(n = 78) 
Patients unsuitable 
for HRV analysis 
(n = 95) 
P Value 
Age (years) 66.2 (53.7 – 74.8) 72.2 (60.7 – 77.1) 0.006 
Male (n,%) 67 (86) 81(85) 1.0 
BMI (kg/m2) 30.1 (26.8 – 32.9) 28.5 (25.0 – 32.6) 0.10 
Neck circumference (cm) 40.5 (38.3 – 42.3) 40.0 (37.5 – 43.0) 0.87 
Waist/Hip ratio 1.02 (0.98 – 1.06) 1.02 (0.97 – 1.06) 0.67 
Ischemic cardiomyopathy (n,%) 43 (55) 46 (48) 0.45 
NYHA (I/II/III/IV) 13/49/16/0 11/61/21/2 0.47 
BNP (pg/ml) 69 (29 – 157) 170 (100 – 320) <0.001 
Left ventricle EF (%) 44 (32 – 58) 37 (27 – 57) 0.08 
Epworth Score 7 (4 – 10) 7 (4 – 10) 0.60 
OSLER duration 40.0 (39.3 – 40.0) 40.0 (22.2 – 40.0) 0.28 
Total Sleep Time (mins) 353 (284 – 405) 349 (291 – 400) 0.82 
Sleep efficiency (%) 73 (60 – 81) 72 (62 – 80) 0.66 
Arousal Index (events/hour) 19.5 (13.5 – 27.2) 18.5 (13.5 – 26.4) 0.49 
AHI (events/hour) 13.6 (6.4 – 25.8) 12.8 (7.2 – 24.1) 0.84 
Time SaO2 <90% (% TST) 1.8 (0.2 – 19.5) 4.8 (0.8 – 22.1) 0.30 
PLMI (events/hour) 6.2 (1.5 – 23.9) 19.1 (4.0 – 49.1) 0.01 
Definition of abbreviations: BMI = body mass index; NYHA = New York heart association class; 
BNP = B-type natriuretic peptide; EF = ejection fraction; OSLER = Oxford sleep resistance test; 
AHI = apnoea-hypopnoea index; SaO2 = finger pulse oxygen saturation; TST = total sleep time; 
PLMI = Periodic Limb Movement Index 
Data are presented as median (interquartile range), or number (%) of patients 
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TABLE E2. DIAGNOSTIC ACCURACY OF %VLFI FOR DETECTION OF SLEEP-DISORDERED BREATHING IN PATIENTS WITH 
CHRONIC HEART FAILURE* 
% VLFI 
parameter 
%VLFI 
threshold 
SDB 
diagnostic 
threshold 
(AHI) 
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Positive 
Likelihood 
ratio 
Negative 
Likelihood 
ratio 
Area 
under 
ROC curve 
%VLFI0-6 
 
>2.23 
>5 
59 
(47 – 71) 
59 
(35 – 82) 
84 
(73 – 95) 
29 
(14 – 44) 
1.43 
(0.78 – 2.63) 
0.70 
(0.42 – 1.15) 
0.55 
(0.39 – 0.71) 
>15 
58 
(42 – 74) 
48 
(33 – 63) 
49 
(34 – 64) 
57 
(41 – 74) 
1.11 
(0.75 – 1.66) 
0.88 
(0.53 – 1.44) 
0.50 
(0.37 – 0.63) 
>20 
56 
(37 – 75) 
45 
(32 – 59) 
33 
(19 – 47) 
69 
(53 – 84) 
1.02 
(0.67 – 1.57) 
0.97 
(0.57 – 1.65) 
0.49 
(0.34 – 0.63) 
>30 
63 
(39 – 86) 
47 
(34 – 59) 
23 
(11 – 36) 
83 
(70 – 95) 
1.17 
(0.75 – 1.83) 
0.80 
(0.40 -1.59) 
0.54 
(0.37 – 0.70) 
>2.4 >15 
47 
(31 – 64) 
50 
(35 – 65) 
45 
(29 – 61) 
53 
(37 – 68) 
0.94 
(0.60 – 1.49) 
1.06 
(0.69 – 1.63) 
0.50 
(0.37 – 0.63) 
%VLFIdiary >2.23 >15 
56 
(39 – 72) 
43 
(28 – 58) 
45 
(31 – 60) 
53 
(36 – 70) 
0.97 
(0.66 – 1.44) 
1.04 
(0.63 – 1.72) 
0.48 
(0.35 – 0.61) 
 
Definition of abbreviations: % VLFI = % very low frequency increment of heart rate variability; SDB = sleep-disordered breathing; AHI 
= apnoea hypopnoea index; ROC = curve receiver operating characteristic curve; %VLFI0-6 = %VLFI measured between midnight and 
0600; %VLFIdiary = %VLFI measured according to diary sleep time. 
*Results are presented with 95% confidence interval  
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TABLE E3. SPECTRAL AND TIME DOMAIN HEART RATE VARIABILITY PARAMETERS IN CHRONIC HEART FAILURE 
PATIENTS WITH AND WITHOUT SLEEP-DISORDERED BREATHING 
 No SDB (n = 41) OSA (n = 31) CSA (n = 5) P Value* 
VLF power (absolute) 3526 (2162 – 7513) 4150 (2835 – 6624) 4960 (3050 – 8012) 0.73 
LF power (absolute) 299 (161 – 629)§ 515 (391 – 1366)§ 380 (89 – 3860) 0.009 
LF power (nu) 68.4 (55.8 – 77.8) 70.7 (57.8 – 82.7) 66.0 (49.0 – 84.5) 0.77 
HF power (absolute) 116 (51.8 – 215) 281 (123 – 468) 123 (46 – 1965)  0.30 
HF power (nu) 31.6 (22.2 – 44.2) 29.3 (17.3 – 42.2) 34.1 (15.5 – 51.0) 0.77 
LF/HF ratio 2.16 (1.27 – 3.51) 2.41 (1.26 – 4.78) 1.94 (1.20 – 6.50) 0.82 
SDNN 68 (55 – 99) 78 (67 – 97) 89 (55 – 118) 0.40 
SDANN 50 (37 – 72) 47 (39 – 66) 51 (34 – 77) 0.92 
SDNNI 35 (27 – 42) 41 (36 – 55) 41 (30 – 54) 0.10 
pNN50 (%) 2.12 (0.92 – 7.49)§ 8.81 (3.32 – 18.58)§ 12.68 (3.04 – 20.44) 0.006 
RMSSD 24 (20 – 36)§ 35 (27 – 57)§ 36 (22 – 110) 0.01 
Mean NN 921 (819 – 1061) 948 (860 – 1036) 944 (862 – 1008) 0.86 
VLF = Very low frequency; LF = Low frequency; HF = High frequency; nu = normalised units; SDNN = standard deviation of NN 
intervals; SDANN = standard deviation of average NN interval during all 5 minute epochs throughout recording; SDNNI = mean of the 
standard deviations of NN intervals during all 5 minute epochs throughout recording; pNN50 = proportion of adjacent NN intervals 
which differ by >50 milliseconds; RMSSD = the square root of the mean of the squares of differences between adjacent NN intervals; 
NN = normal to normal interbeat interval 
*p value for comparison between CHF patients without SDB (‘No SDB’), CHF patients with OSA and CHF patients with CSA, by 
Kruskal Wallis test. §p<0.005 for difference between CHF patients with OSA and patients without SDB (‘No SDB’)  
Data are presented as median (interquartile range) 
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Figure E1 
 
Mean Difference 
-0.2/hour
+1.96 S.D. 
12.7/hour
-1.96 S.D. 
13.0/hour
 
Figure E1. Bland-Altman plot showing mean difference and 95% limits of agreement for measured apnoea hypopnoea index (AHI) 
and 3% oxygen desaturation index (ODI) in CHF patients. (S.D. = standard deviation) 
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Figure E2 
 
 
 
Figure E2. Correlation between apnoea hypopnoea index and 3% oxygen desaturation index in 
CHF patients  
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